Chimerix focusing efforts on CMV and adenovirus pivotal trials
Chimerix announced that after discussion with the FDA, the company is ceasing further participation in all current and future clinical studies of brincidofovir for Ebola Virus Disease, including the study announced in December in Liberia sponsored by investigators at the University of Oxford. January 30, 2015